Granules Eyes Double-Digit Growth as Transformation Gains Traction
Q1 momentum signals a company in acceleration: revenue up 22%, EBITDA surged 37%. Q2 will test whether the pharmaceutical play can sustain that clip while executing on a pipeline overhaul—from CDMO ambitions to FDA filings—and managing a reshaped shareholder base.
The Headline: Momentum Sustained, Transformation in Motion
Granules delivered a blowout Q1 FY-2027: ₹1,477 Cr in revenue (22% YoY growth), ₹339 Cr EBITDA (37% YoY, 22.9% margin), and PAT surged 60% YoY. This is the company's strongest first quarter on record. For Q2, the Street is expecting that momentum to persist—analysts forecast low-to-mid teens revenue growth and margin resilience in the 22–23% range—but the real test lies in whether the company can thread the needle: maintain pricing/volume discipline in US/Europe (which drives 94% of sales), execute on newly incorporated subsidiaries in Brazil and Mexico, and ramp the recent CDMO acquisition (Senn Chemicals AG) while managing an FDA pipeline overhaul.
~₹1,420–1,500 Cr
On-plan mid-teens growth; Q1 set ₹1,477 Cr bar; Q2 typically flatter but momentum should support growth
~22–23%
Q1 delivered 22.9%; sustaining requires stable US/EU pricing and volume stability
Double-digit
Street estimates FY27 EPS at ₹30.80 (24% growth); Q2 should deliver continuation
Likely yes
No explicit FY27 revenue/EBITDA guidance found; but Q1 momentum suggests company tracking forward expectations
What a Strong vs Weak Print Looks Like
Strong Q2: Revenue ≥₹1,450 Cr (≥16% YoY), EBITDA margin ≥22.8%, PAT growth ≥15% YoY. Commentary mentions volume traction in new geographies (Brazil, Mexico CDMO ramp), progress on FDA filings (Ruxolitinib and other first-to-file candidates), and pricing stability in US/EU. Management reiterates confidence in mid-to-long-term margin trajectory (targeting 12.7% net margins by FY28 per analyst commentary). Weak Q2: Revenue <₹1,350 Cr (<12% YoY), EBITDA margin <21.5%, flat or declining PAT YoY. Would signal US/EU volumes softer than expected or pricing pressure. Delays in FDA remediation work or first-to-file approvals would also register as disappointment given recent corporate event cycle (webinar, ANDA filing announcements).
Street View: Bullish, But Valuation a Debate
Since Last Quarter: Capital Raise, Filings, and New Ventures
Sep 16–25, 2026
Warrant conversion: 2.49 Cr shares allotted to promoter group; Dr. Krishna Prasad and Uma Devi subsequently sold 1.72 Cr + 2.48 Cr shares (Sept 11, 25) at ₹872.50 and open market
Capital raise (~₹1,463 Cr gross) to fund growth; promoter stake diluted from 38.82% (Q1) to ~30% (est.), but household brand visibility intact. Sales suggest confidence in valuation and focus on diversification.
Oct 2–22, 2026
Incorporation of wholly-owned foreign subsidiaries: TRITON FARMACEUTICA DO BRASIL LTDA (Brazil) and TRITON FARMACEUTICA S.A. de C.V. (Mexico)
Signals geographic expansion and local manufacturing/distribution footprint in LATAM. Ramp timelines TBD; watch for commentary on capex and timeline.
Oct 7, 2026
ANDA filing: Ruxolitinib ER Tablets with Paragraph IV certification and first-to-file claim
Adds oncology/specialty product to US pipeline; first-to-file status means 180-day exclusivity if approved. Key value driver for medium-term growth. Approval timeline typically 10–12 months; Q2 result unlikely to have material update on this.
Sep 29, 2026
Webinar: 'Granules India 2.0 Comprehensive Transformation Underway'—outlines four growth engines
Management reiterating transformation narrative. Will likely reference this on earnings call; watch for specifics on pipeline velocity and margin roadmap.
Oct 1, 2026
Trading window closure for insiders (until 48 hours post-result declaration)
Routine compliance; confirms board will announce results on or around Nov 2 as intimated.
What to Watch on Result Day
1 · Volume and pricing trends in US/EU
94% of sales come from exports. Management should provide colour on (a) tender/contract wins vs losses, (b) pricing trajectory in key markets (Europe, US generics), and (c) volumes by segment (APIs, intermediates, finished dosage). Any softness here re-rates the stock.
2 · Margin trajectory and FY27/FY28 guidance
Q1 delivered 22.9% EBITDA. Street is modeling 22–23% for Q2 and longer-term 24–26% by FY28 (per analyst consensus). Guidance on capex for Genome Valley, LATAM subsidiaries, and Senn Chemicals ramp will determine margin accretion. Watch for any guidance reset.
3 · FDA remediation and first-to-file pipeline updates
Ruxolitinib ANDA just filed (Oct 7). Management should update on (a) status of prior FDA warning letters/compliance actions, (b) number of ANDAs in pipeline, (c) oncology/specialty play timeline. This is the growth story beyond organic export momentum.
Granules India is at an inflection: Q1 proved the export-led API/CDMO business can drive 20%+ growth while maintaining comfortable margins. Q2 will confirm whether that's repeatable or an outlier. The case for the stock rests on three pillars: (1) sustained US/EU volume and pricing discipline; (2) execution on the CDMO transformation (Senn Chemicals integration, LATAM footprint); and (3) FDA wins (Ruxolitinib and other first-to-files). A beat on revenue and margin, with confident commentary on the pipeline, confirms the bull thesis. A miss—whether on volume, pricing, or FDA progress—would raise execution questions and likely trigger a pullback from the ₹822 entry.